Feb. 27, 2004 — Scheduled maintenance with infliximab reduced hospitalizations and improved healing compared with episodic dosing for patients with Crohn's disease, according to the results of a ...

ORLANDO – Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, a researcher ...

Please provide your email address to receive an email when new articles are posted on . Patients with inflammatory bowel disease who received home infusions of Remicade had higher rates of ...

Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, according to research ...

Therapeutic persistence with infliximab was associated with signifi cantly fewer ulcerative colitis patients requiring hospitalization; once hospitalized, patients with therapeutic persistence had ...

Please provide your email address to receive an email when new articles are posted on . In a prospective, observational cohort study, researchers evaluated 186 patients with IBD previously dosed with ...

All eligible patients received an intravenous infusion of infliximab (Remicade, Centocor) at a dose of 5 mg per kilogram of body weight at weeks 0, 2, and 6. A response 12 was defined as a reduction ...

LAS VEGAS, Nev., October 23, 2006 -- Patients with ulcerative colitis (UC) treated with REMICADE® (infliximab) had an approximate 50 percent reduction in mean number of hospitalizations per year ...

June 13, 2006 -- The U.S. Food and Drug Administration (FDA) has approved a 2000-IU (5-mL) dose for antihemophilic factor VIII [recombinant] infusion; and an expanded indication for infliximab ...

Remicade comes as a powder. A healthcare professional mixes the powder with liquid to form a solution, which they give as an intravenous (IV) infusion. (This is an injection into a vein given over ...

A second biosimilar to infliximab, marketed as Remicade by Johnson & Johnson, has received FDA approval. Infliximab-abda (Renflexis) was developed by Samsung Bioepis/Merck and has been approved for ...

Sustained use of the drug infliximab could offer substantial clinical benefit to people with Crohn’s disease, conclude authors of a study in this week’s issue of THE LANCET. Crohn’s disease is a ...